---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-294899"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2022-11-30T23:59:59+00:00"
generated_at: "2026-06-21T11:42:21.371271+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aeglea Biotherapeutics appoints Jeffrey M. Goldberg as President and CEO

## Summary
- Jeffrey M. Goldberg appointed President, CEO, and Class III director effective Nov 29, 2022.
- Jim Kastenmayer resigns as Interim CEO, remains General Counsel and Corporate Secretary.
- Goldberg receives $600k base salary, up to 50% cash bonus, and $35k housing allowance.
- Stock option for 1,884,838 shares granted, vesting 1/4 on first anniversary then monthly.

## SEC filing metadata
- accession: 0001193125-22-294899
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2022-11-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/0001193125-22-294899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/d376158d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-294899
- JSON: https://secwatch.observer/filing/0001193125-22-294899.json
- Plain text: https://secwatch.observer/filing/0001193125-22-294899.txt

## Key facts
- Executive change
  Jeffrey M. Goldberg was appointed as President and Chief Executive Officer at Spyre Therapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On November 28, 2022, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Jeffrey M. Goldberg, age 50, as President and Chief Executive Officer, and as a Class III director, effective November 29, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/0001193125-22-294899-index.htm
- Executive change
  Jim Kastenmayer resigned as General Counsel and Corporate Secretary at Spyre Therapeutics, Inc..
  - Action: resigned
  - Role: General Counsel and Corporate Secretary
  source text: In conjunction with the appointment of Mr. Goldberg, Jim Kastenmayer resigned from his position as the Company’s Interim Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/0001193125-22-294899-index.htm
- Executive change
  Jeffrey M. Goldberg was appointed as Class III director at Spyre Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: On November 28, 2022, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Jeffrey M. Goldberg, age 50, as President and Chief Executive Officer, and as a Class III director, effective November 29, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312522294899/0001193125-22-294899-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.